International Diploma in Molecular Biology
Applied to Clinical Oncology (Third edition)

Background

The main objective of the International Diploma in Molecular Biology Applied to Clinical Oncology is to provide an excellence international educational program with high academic and professional European experts in the different oncological areas for the diagnosis and treatment of cancer-based on molecular biology. Link: www.internationaloncologydiploma.com

Academic Endorsement

The present program has the following endorsements:

➢ GIGA Cancer Center Institute. Liege University (Link: http://www.giga.uliege.be)
➢ University Hospital Center of Liège (Link: http://www.chu.ulg.ac.be)
➢ Belgian Society of Medical Oncology (Link: www.bsmo.be)

Latin America Endorsement and Diffusion:

➢ Brazilian Society of Clinical Oncology (Link: https://www.sboc.org.br/)
➢ ACHO- Colombia (Link: http://www.acho.com.co/)
➢ Colegio Mexicano de Oncología Médica (Link: http://www.cmom.org.mx/)
➢ GECO Peru (Link: http://www.gecoperu.pe/)
➢ Asociación Argentina de Oncología Clínica (Link: http://aaoc.org.ar/)
➢ Projeto CURA – LACOG (Link: http://www.projetocura.org)

Program Duration: 6 months (April to October 2020)
Academic Hours: 200 hours
Modality: In class sessions (25 and 26 of April 2020 – Lima, Perú and 3 and 4 of October, 2020 in Mexico, Mexico City) and on-line
Program Language: English and Spanish
Mobile App: Molecular Oncology

Cost

Inscription: 2,500 USD (includes program access with educational materials, educational platform, mobile App and in class sessions with coffee breaks and buffet lunches).

Members of endorsement organizations will have a 10% discount of the total inscription.

Program coordination can arrange hotel reservations with cooperation programs for hotels of 3, 4 and 5 stars including the conference hotel.
Note: hotels and flight tickets are not included in the inscription fee.

Inscription payment can be implemented by credit card (PayPal- online website) or wire transfer.

Contact information for inscriptions and payments: coordination@internationaloncologydiploma.com

Payment

After submitting the online inscription form you will receive a confirmation letter with payment instructions, by e-mail.

Participants are always responsible for the payment of the tuition fee, even if the employer or an organization will pay the tuition fee. Participants are requested to forward the invoice to our financial department and to make sure the tuition fee is paid before the deadline.

Cancellation Policy

If you have registered but are unable to attend, a substitute delegate is welcome at no extra charge. Please, inform the program coordination in advance by E-mail.

- Cancellations must be sent by E-mail to the program coordination.
- A cancellation/administration fee of 300 USD will be charged in all cases of cancellation before March 1st, 2020.
- In case of cancellation after March 1st, 2020 no refund will be possible, and the full amount will remain due.

Fellowships

Each year, the program provides an invaluable opportunity to participate in the International Diploma.

Each Fellowship is a stimulating challenge for talented young oncologists or in related areas who seek leading careers in oncology areas in public institutions.

Fellowships cover tuition fee and accommodation in Lima-Peru and Mexico City-Mexico. All additional costs – travel expenses, subsistence, etc. – are at the participants’ expense.

Applicants who meet each of the following requirements will be considered for a complete or partial Fellowship:

- You have not attended the program in the past.
• You are currently working in public institutions in oncology area.
• Limited economic resources to cover the inscription fees.

If you are interested in registering for the fellowship program, please make sure you read the Participant Profile to ensure you are eligible for the fellowship.

To submit your fellowship application, you need to send each of the following documents to coordination@internationaloncologydiploma.com:

1. A letter of motivation (max. 400 words!), with a focus on academic excellence and ambitions to pursue a successful oncology areas career. Why should we choose you? Also make sure that you explain why you have a particular interest in molecular oncology area and the reasons for a fellowship application?
2. A curriculum vitae, including:
   • A list of educational institutes attended + corresponding dates
   • Degree(s) obtained or expected to obtain
   • Work experience + corresponding dates of employment for each position held
   • Research experience + a complete list of publications
3. A copy of diplomas with stamps and/or certification from the institute concerned
4. Two recent letters of recommendation
5. A copy of your passport

Please note that we only accept and assess complete application packages

Application Deadline: 1 of February 2020. You will be informed about the outcome of the selection procedure by the end of February the latest.

Project Coordination

Europe Coordination: Guy Jerusalem MD., PhD
Latin America Coordination: María del Carmen Cabezas MD., PhD
App-Mobile Application: Molecular Oncology
Europe Coordinator

Guy Jerusalem MD., PhD is head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer, among others.

Latin America Coordinator

María del Carmen Cabezas MD., PhD, did her specialty studies and PhD at the University of Liège-Belgium (ULg), with a training in Epidemiology at the Erasmus University (Rotterdam-The Netherlands), and Problem Based Learning at Maastricht University, is General Manager of Health & Research Services, main professor in the Faculty of Medicine of the Pontifical Catholic University of Ecuador. At the publication level, she is board member of Science Direct Group and the International Journal of HIV/AIDS Prevention, peer reviewer of several international journals with a high impact factor such as AIDS & Behavior, Peer J, among others. Researcher and Coordinator of clinical studies of phase I-IV, epidemiological, pharma-economic and public health researchs. She has several publications in international journals as main author and co-author in epidemiology, public health, and pharma-economic topics. Her main interest is the development of international education programs with European and Canadian organizations in support of the education system in Latin America.
Program Modality:

In class sessions, with established academic meetings (Saturday and Sunday) on the dates specified in the program and on-line. The training of the participants is complemented by online education tools on the ZOOM visual platform. All participants will have total access to the training through videos, teleconferences and educational materials.

The virtual program will be available on-line (www.internationaloncologydiploma.com) and by mobile app (Molecular Oncology), to assure a complete program access.

Faculty

- Adelin Albert M.Sc., PhD. Professor Emeritus at Liege University (ULg). Professor at the Erasmus Summer Course (ESP) program, Netherlands Institute for Health Sciences (NIHES), University of Rotterdam, Netherlands.
- Guy Berchem MD., PhD. Medical oncologist at the Hospital Center of Luxembourg (CHL), head of the research laboratory Experimental Hemato-Oncology Laboratory (LHCE) at the Public Health Research Center (CRP-Santé) in Luxembourg, president of the National Cancer Institute (INC) and Past president of the Luxembourg Oncology Society (SLO).
- Vincent Bours MD., PhD. Head of the center for human genetics at the University Hospital Center (CHU) of Liège and professor at University of Liège (ULg).
- Pierre Close M.Sc., PhD. Principal Investigator of FNRS, head of the Laboratory of Cancer Signaling at GIGA Institute and professor at ULg.
- Joelle Collignon MD. Researcher and head of clinics at CHU of Liège.
- Jacques De Grève MD., PhD. Emeritus Head of medical oncology and Emeritus Head of Laboratory of Molecular Oncology at the Free University of Brussels (ULB), Past president of the Belgian Society of Medical Oncology (BSMO). President of the Belgian Working party for the Development of National Cancer Guidelines. Emeritus Professor of medical oncology at ULB.
- Pierre Frères MD. PhD. Medical Oncologist, and Researcher at CHU of Liège.
- Rodrigo Dienstmann, MD PhD Leader in the Molecular Prescreening Program for Precision Medicine, Vall d’Hebron Institute of Oncology, Spain and principal investigator, Oncology data Science Group, Vall d’Hebron Institute of Oncology, Spain.
- Piet Dirix MD., PhD. Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014.
- Christine Gennigens MD. Head of clinics at CHU of Liège and member of the medical council at CHU of Liège.
- Enrique Grande, MD., Msc.,PhD, has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center.
- Michael Herfs BSc., Msc.,PhD. He holds a PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, FNRS of Belgium and ULg.
- Guy Jerusalem MD., PhD. Head of Medical Oncology at CHU of Liège, professor at ULg and local principal investigator for the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG).
➢ Laurence Lousberg MD. Head of Clinic, Department of Medical Oncology CHU of Liege. Experience in trial research phases I-III. Her therapeutic area is in solid tumors and breast cancer.

➢ Olivier Malaise MD., Ph.D. Has a Master in Rheumatology, a PhD in osteoarthritic area a Post-doctoral researcher at the Institute of Regenerative medicine and biotherapies in Montpellier, France. Staff of the rheumatology service at CHU of Liege in Belgium.

➢ Rodrigo Ramella Munhoz, MD. Director of medical oncology fellowship program and specialist in immunotherapy at Sirio Libanes Hospital in Sao Paulo- Brazil. Attending in the Oncology Center and Melanoma and Sarcoma Group at Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Brazil.

➢ Agnès Noel MSc., PhD. Director of the research center GIGA- cancer. President of the thematic graduate school in experimental cancerology of FNRS of Belgium. Professor and president of the council of research and valorization in health sciences at ULg.

➢ Elisa Onesti MD. Head of Clinic, Medical Oncology at CHU of Liège, PhD student at ULg (GIGA research center, laboratory of human genetic).

➢ Brieuc Sautois MD., PhD. Head and professor of Clinics in the department of medical oncology at CHU of Liège, board of the oncology certification- Belgium.

➢ Martin Angel MD., Oncologist at Instituto Alexander Fleming in Buenos Aires Argentina.

Short Curriculum Vitae of Program Professors

Adelin Albert M.Sc., PhD

Prominent Belgian professor. He retired as an Emeritus Professor in 2013 but he is still involved in teaching and consultancy activities for universities and hospitals. His research interests include multivariate logistic regression, survival analysis, clinical decision-making, quality control and epidemiology. He acquired a wide experience in the development and application of statistical methods in medicine and biomedical sciences. Author or co-author of over 600 international scientific articles in the field of biostatistics and medical computing in prestigious journals.
Guy Berchem MD., PhD

Founder and head of Experimental Cancer Research Laboratory at Health Institute of Luxembourg (LIH). Past president of the Luxemburg Society of Medical Oncology and holds a clinical position leading the oncology platform at Hospital Medical Center of Oncology in Luxembourg. He has more than 70 international scientific publications as author and co-author.

Vincent Bours MD., PhD

Head of the department of human genetics at the University Hospital Center (CHU) of Liège. Professor of genetics at University of Liège (ULg). Patent: Circulating microRNAs for diagnosis of breast cancer. He has more than 220 international publications in high impact factor journals.

Pierre Close M.Sc., PhD

Principal Investigator of National Fund for Scientific Research (FNRS), head of the Laboratory of Cancer Signaling Group of Applied Genoproteomics (GIGA) and professor of the University of Liège (ULg). He has had a great interest in new mechanisms promoting tumor adaptation to identify novel therapeutic strategies in the treatment of invasive or resistant human cancers. Author and co-author of many international scientific publications in high impact factor journals such as: Nature, Cell, Oncogene, Journal of Biological Chemistry among others.
Joelle Collignon MD

Head of clinics at University Hospital Center (CHU) of Liège. Researcher in clinical studies phase I-IV. She has high experience in solid and gastrointestinal tumors. She has more than 56 scientific publications as author and co-author.

Rodrigo Dienstmann, MD PhD

Currently, he is collaborating in Computational Oncology, Sage Bionetworks, Fred Hutchinson Cancer Center, Seattle, USA; Leader in the Molecular Pre-screening Program for Precision Medicine, Vall d’Hebron Institute of Oncology, Spain and principal investigator of several clinical trials. Author and co-author of more than 50 international publications in prestigious journals. Associate Editor in the Journal of Clinical Oncology Precision Oncology and Daily Reports of European Society for Medical Oncology (ESMO) Congress and inviter peer reviewer of prestigious journals such as Jama Oncology, Plos One, Annals of Oncology among others.

Piet Dirix MD., PhD

Associate Professor at University of Antwerp (Belgium) from August 2014, Associate Professor at KU Leuven (Belgium) from August 2013 and staff member at Iridium Cancer Network (Antwerp, Belgium) from May 2014. He obtained his PhD in medical sciences (KU Leuven, Belgium) and a specialist in radiation oncology (KU Leuven, Belgium). Professor in international ESTRO courses. Editorial board member: Belgian Journal of Medical Oncology (BJMO) and World Journal of Radiology (WJR). Author and co-author of several publications in prestigious journals.
Jacques De Grève MD., PhD

Emeritus head of medical oncology and head of the laboratory of molecular oncology and medical oncology department at the Hospital of Free University of Brussels (ULB). Past chairman of the Belgian Society of Medical Oncology (BSMO), editor in chief of the Belgian journal of medical oncology, chairman of the Belgian working party for the development of national cancer guidelines. He is emeritus professor of medical oncology and emeritus coordinator of the course “Molecular targets in Cancer” at the ULB as well as coordinator of a national interuniversity postgraduate course in medical oncology. He has a special interest in genomic-driven translational therapeutic studies. He has 150 international scientific publications in high impact factor journals.

Pierre Frères MD., PhD

Physician of clinical oncology at University Hospital Center (CHU) of Liège. Has a PhD in the “Role of circulating microRNA in breast cancer” at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA) cancer, human genetics of University of Liège (ULg). He has 21 international publications in oncology as author and co-author.

Christine Gennigens MD

Head of clinics at University Hospital Center (CHU) of Liège, and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. She has more than 30 scientific publications as author and co-author.
Enrique Grande, MD., Msc.,PhD

Enrique Grande, MD., Msc.,PhD, has been recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. He is focus on the research on Genitourinary and Endocrine tumors and takes active collaboration in the development of the Translational Research and Early Drug Development Unit. He was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a Master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). A published author of more than 150 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumours (GETHI). Dr Grande is Professor at the Francisco de Vitoria University, editor of several international journals. Dr Grande has participated in the most recent trials in the field of RCC that led to the approval of the new drugs we have now available.

Michäel Herfs M.Sc., PhD

PhD in biomedical and pharmaceutical sciences. Scientific collaborator in Telelife, Belgian National Fund for Scientific Research (FNRS), University of Liège (ULg). He completed his post-doctorate in the laboratory of Professor Christopher Crum at Harvard University (Brigham and Women’s Hospital, Boston). Since 2006, his interest has focused on microenvironment/origin and HPV tumors. He has more than 40 international publications in high impact factor journals.
Guy Jerusalem MD., PhD

Head of medical oncology, director of the breast clinic and research coordinator in the area of medical oncology at University Hospital Center (CHU) in Liège, Belgium. Professor of medical oncology at University of Liège (ULg). Principal investigator in the International Breast Cancer Study Group (IBCSG), the Breast Group of the European Organization for Cancer Research and Treatment (EORTC) and the Breast Cancer International Research Group (BCIRG). Steering committee of several international clinical studies including CONFIRM, SOLE, Bolero 3, Aphinity, SNAP, Bolero 6 and Monaleesa 3. Co-author of 8 book chapters and author of articles published extensively in international journals such as Lancet Oncology, Journal of Clinical Oncology, Blood, The Oncology, Hematology, Annals of Oncology, Clinical, Cancer Research, Cancer Treatment Reviews, Breast Cancer, Journal of the National Cancer Institute, European Journal of Cancer among others.

Laurence Lousberg MD

Head of Clinic, Department of Medical Oncology CHU of Liege. Experience in trial research phases 1-3. Her therapeutic area is in solid tumors and breast cancer. Author and coauthor of oncology publications.
Olivier Malaise MD., Ph.D

Has a Master in Rheumatology, a PhD in osteoarthritic area a Post-doctoral at the Institute of Regenerative medicine and biotherapies in Montpellier, France. He is member of the task force “immuno-rheumatology” of the Belgian Society of Rheumatology and Member of the task force “osteoporosis and bone disease” of the Belgian Society of Rheumatology. His scientific interest and current research area are the articular involvement of anti-cancer treatments, especially immunotherapies. Author and co-author of several publications in prestigious journals.

Rodrigo Ramella Munhoz, MD.

Director of medical oncology fellowship program and specialist in immunotherapy at Sirio Libanes Hospital in Sao Paulo- Brazil. Attending in the Oncology Center and Melanoma and Sarcoma Group at Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Brazil. He implemented a clinical fellowship at Sylvester Comprehensive Cancer Center and Jackson Memorial Hospital. His scientific interest and current research area are advanced cutaneous squamous cell carcinoma, Study of the Anti-PD1 Antibody PDR001. Author and co-author of several publications in prestigious journals.

Agnès Noël M.Sc., PhD

Recognized Belgian researcher. Director of the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA)-cancer. President of the thematic graduate school in experimental cancerology of the National Fund for Research (FNRS) of Belgium. Professor of molecular cell biology and molecular oncology and president of the council of research and valorization in health sciences at the University of Liege (ULg). Author and co-author of more than 160 international scientific articles.
Elisa Onesti Concetta MD., PhD (c)

Currently works as an oncologist at medical oncology department University Hospital Center (CHU) of Liège, Belgium. She is PhD student at the research center Interdisciplinary Cluster in Applied Genoproteomics (GIGA) Research Center, Human Genetics Laboratory, University of Liège (ULg). She has carried out preclinical research at the "Institute of Cancerology Gustave Roussy", Unit INSERM U981, Villejuif, France. She has more than 40 international scientific publications, abstracts and posters as author and co-author.

Brieuc Sautois MD., PhD

Head and professor of clinics at the department of oncology University Hospital Center (CHU) of Liège, researcher of clinical trials of phase I-III. He is currently involved in the daily clinical management of patients with solid tumors with interest in those of the urinary tract and head and neck. He has more than 40 international scientific publications as author and co-author.

Invited Speaker: side effects management with immunotherapy in Latin America: clinical cases

Martin Angel MD

Medical Oncologist Staff at Instituto Alexander Fleming in Buenos Aires -Argentina since 2014. High experience in immunotherapy in oncology area. Dr. Angel has participated in several clinical trials related to new immunotherapy drugs and he has an important knowledge in immunotherapy sides effects management in oncology patients.
Attendance and Participation of Program - Regulations

Participants must complete a minimum of 50% in attendance for in class sessions (at least 1 meeting) and 80% in self-learning program (quizzes), online courses, module exams and tutorial activities to access the final exam. To successfully complete the program, a minimal of 80% must be achieved. Any violation of the stipulated ethic code entails the immediate withdrawal from the program.

Module 1
Dates: April to June 2020

Module 2
Dates: June to August 2020

Module 3
Dates: August to October 2020

In live sessions

Lima-Peru on 25 and 26 of April 2020

Mexico DF-Mexico on 3 and 4 of October 2020

General Topics

<table>
<thead>
<tr>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>From seed and soil to pre-metastatic niche concepts.</td>
</tr>
<tr>
<td>Angiogenesis and lymphangiogenesis</td>
</tr>
<tr>
<td>Cancer-Associated Fibroblasts: what is new?</td>
</tr>
<tr>
<td>Matrix metalloproteinases: turning clinical failure to innovative perspectives</td>
</tr>
<tr>
<td>PI3K pathway</td>
</tr>
<tr>
<td>Cancer stem cells</td>
</tr>
<tr>
<td>Minimal residual disease</td>
</tr>
<tr>
<td>Systemic mechanism of resistance to therapy</td>
</tr>
<tr>
<td>Molecular Classification of Gastrointestinal Malignancies</td>
</tr>
<tr>
<td>Biology of cancer: viral carcinogenesis</td>
</tr>
<tr>
<td>Molecular imaging in oncology</td>
</tr>
<tr>
<td>NTRK fusions: new targets for cancer therapy</td>
</tr>
<tr>
<td>Precision medicine, clinical applications and precision initiatives</td>
</tr>
<tr>
<td>Laboratory Precision Medicine</td>
</tr>
<tr>
<td>Somatic mutations</td>
</tr>
</tbody>
</table>
Breast cancer: ER positive, HER2 neg: standard adjuvant therapy; ER positive ABC: endocrine monotherapy versus combined treatment approaches; mechanism of endocrine therapy resistance; role of CDK4-6 inhibitors, everolimus and new promising targeted agents; sides effects management. Triple negative breast cancer. Subgroups and potential targets for therapy; role of PARP inhibitors; new promising drugs; standard therapy in the adjuvant and metastatic setting. HER positive advanced breast cancer: standard therapies for HER2 positive ABC: optimal sequence and expected outcome; mechanism of resistance to therapy, new promising drugs

Workshop: clinical case(s) OE pos HER2 negative breast cancer (interactive group discussion)

Workshops: clinical case(s) breast cancer HER2 positive or triple negative (interactive group discussion). ER positive HER2 negative breast cancer

Workshop: clinical case(s) clinical management of hereditary breast cancer (interactive small group discussion)

Ovarian cancer

Metastatic cancer of the uterus (cervical and endometrial cancer)

ALK and clinical cases of targeted therapy in NSCLC (anti-EGFR).

Lung cancer: translational efforts

EGFR mutated NSCLC

Prostate cancer: management of oligometastatic prostate cancer; intermittent versus continuous androgen deprivation, chemotherapy (docetaxel, cabazitaxel), bone targeting agents, abiraterone, enzalutamide: optimal sequence and side effects of standard treatment options; placing DNA repair into the evolving treatment landscape

Bladder cancer

Biological basis of clear cell renal cell carcinoma (CCRCC)

Patient selection for different treatments in metastatic renal cancer

Testicular Cancer

Metastatic colon cancer

Adjuvant Colon cancer

Cholangiocarcinoma: standard systemic therapy and role of targeted agents.

Gastric cancer

Pancreatic cancer

Melanoma BRAF V600 Mutations and Melanoma Wild Type

Workshop: melanoma cases

Hereditary cancers

Hereditary cancers: different management compared to sporadic cancers?

Head and neck tumors
Virtual Platform

A personalized e-learning platform will support the access to the contents of each module with their respective evaluations and certifications. In addition, a mobile application tool will provide an interactive webinars access.

Final Exam

Saturday 31 of October 2020 at 10a.m. (On-line)

Virtual Platform

Graduation

November 2020 – Colonster Castle (University of Liege), Liege, Belgium (Optional participation).
Includes GiGA center visit, scientific meetings and interaction with CHU oncology service.

In case of absence to the graduation ceremony, diploma will be delivered by DHL to the participants.